Percheron Therapeutics LimitedASX: PER

ATL1102 for MS Phase IIb IND submitted to the FDA

Jun 26, 2017 at 12:21 AM UTC · Issued by Percheron Therapeutics Limited

Percheron Therapeutics Limited has released a press release.

View Attachment